Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Sunshine Biopharma (SBFM) over the last 11 years, with Q3 2025 value amounting to $96163.0.

  • Sunshine Biopharma's Depreciation & Amortization (CF) rose 4878.08% to $96163.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $298888.0, marking a year-over-year increase of 4908.54%. This contributed to the annual value of $223527.0 for FY2024, which is 4987.03% up from last year.
  • Per Sunshine Biopharma's latest filing, its Depreciation & Amortization (CF) stood at $96163.0 for Q3 2025, which was up 4878.08% from $72533.0 recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Depreciation & Amortization (CF) peaked at $96163.0 during Q3 2025, and registered a low of $789.0 during Q3 2022.
  • Over the past 5 years, Sunshine Biopharma's median Depreciation & Amortization (CF) value was $34884.0 (recorded in 2023), while the average stood at $33898.3.
  • Per our database at Business Quant, Sunshine Biopharma's Depreciation & Amortization (CF) crashed by 7521.21% in 2022 and then surged by 461482.89% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $3184.0 in 2021, then soared by 496.01% to $18977.0 in 2022, then skyrocketed by 123.18% to $42353.0 in 2023, then soared by 54.41% to $65399.0 in 2024, then surged by 47.04% to $96163.0 in 2025.
  • Its Depreciation & Amortization (CF) was $96163.0 in Q3 2025, compared to $72533.0 in Q2 2025 and $64793.0 in Q1 2025.